title: Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update.
abstract: The Hedgehog inhibitors are promising alternative for patients with advanced basal cell carcinoma that are not amenable to radiotherapy or surgery. Sonidegib, also known as LDE225, is an orally available SMO antagonist that was recently approved by the US FDA for the treatment of patients with locally advanced basal cell carcinoma. This article will provide an overview of the pharmacology and pharmacokinetics of sonidegib and in-depth analysis of the BOLT trial with additional data from the 12-month update. The present challenges associated with Hedgehog inhibitors will also be discussed.
authors.affiliation: Department of Dermatology, The University of Texas McGovern Medical School at Houston, Houston, TX, USA.
authors.forename: Leon
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Dermatology, The University of Texas McGovern Medical School at Houston, Houston, TX, USA.
authors.forename: Sirunya
authors.initials: S
authors.lastname: Silapunt
authors.affiliation: Department of Dermatology, The University of Texas McGovern Medical School at Houston, Houston, TX, USA.|Departments of Dermatology & Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Migden
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D002986:Clinical Trials as Topic; D005500:Follow-Up Studies; D053823:Hedgehog Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D051379:Mice; D011725:Pyridines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D000072086:Smoothened Receptor / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001713:Biphenyl Compounds; D053823:Hedgehog Proteins; D011725:Pyridines; D000072086:Smoothened Receptor; C561435:sonidegib
keywords: BOLT trial; basal cell carcinoma; sonidegib